Crossmark

Cost-effectiveness of anti-vascular endothelial growth factor and macular laser treatments for people with centre-involving diabetic macular oedema and central retinal thickness of at least 400 micrometres

Crossref DOI link: https://doi.org/10.1038/s41433-025-04015-6

Published Online: 2025-09-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Luckham, Kirsty https://orcid.org/0009-0009-2131-6243
Tebbs, Hannah

Dadswell, Clare

Yosef, Ahmed

Claxton, Lindsay

Kelley, Kate

Taske, Nichole

Burgess, Philip I.

Dinah, Christiana https://orcid.org/0000-0002-0815-4771
Lois, Noemi https://orcid.org/0000-0003-2666-2937
Mohiuddin, Syed https://orcid.org/0000-0003-4585-3392
License Information

Text and Data Mining valid from 2025-09-19

Version of Record valid from 2025-09-19
More Information

Article History

Received: 30 April 2025

Revised: 29 August 2025

Accepted: 11 September 2025

First Online: 19 September 2025

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below